Da angiogénese à terapêutica oncológica antiangiogénica

Autores

M. Jorge Freitas Almeida Instituto Português de Oncologia do Porto, Porto

DOI:

https://doi.org/10.31877/on.2013.23.01

Resumo

Os avanços ocorridos na área da biologia molecular possibilitam uma melhor compreensão dos mecanismos de carcinogénese. Nestes, destaca-se a angiogénese como o processo através do qual as células tumorais estimulam a formação dos novos vasos sanguíneos necessários para o fornecimento dos nutrientes essenciais para seu crescimento acelerado. A angiogénese tumoral é regulada pela produção de estimuladores da angiogénese, incluindo membros da família dos factores de crescimento do endotélio vascular (VEGF) e dos factores de crescimento dos fibroblastos (FGF).

Os tumores podem activar inibidores angiogénicos como a angiostatina e a endostatina, que podem modular a angiogénese, tanto no local do tumor como em locais metastáticos. O uso de inibidores angiogénicos como drogas antineoplásicas está actualmente sob intensa investigação. Tais agentes podem ter uma toxicidade reduzida e serem menos susceptíveis de gerar resistência do que as drogas citotóxicas convencionais. Os ensaios clínicos estão em andamento para desenvolver estratégias de tratamento ideal com os agentes antiangiogénicos.

Downloads

Não há dados estatísticos.

Referências

Brown JM, Giaccia AJ. Enzyme eliminated by cancer cells holds promise for cancer treatment. April 1, 1998. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Research 58: 1408–16. PMID 9537241

Bergers G, Benjamin LE (June 2003). “Tumorigenesis and the angiogenic switch”. Nature Reviews. Cancer 3 (6): 401–10. doi:10.1038/nrc1093. PMID 12778130

Rafii S, Heissig B, Hattori K (May 2002). Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors. Gene Therapy 9 (10): 631–41. doi:10.1038/sj.gt.3301723. PMID 12032709

Ozer E, Ozkal S, Karademir S, et al: Angiogenesis and p53 and H-ras mutations in pancreatic ductal adenocarcinoma. Analytical & Quantitative Cytology & Histology 1999; 21(6):473-476

Maclean Ab, Reid Wm, Rolfe KJ, et al: Role of angiogenesis in benign, premalignant and malignant vulvar lesions. Journal of Reproductive Medicine. 2000; 45(8):609-612.

Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology. 2005; 69 Supply 3:25-33.

Folkman J, Klagsbrun M (January 1987). Angiogenic factors. Science (New York, N.Y.), 235 (4787):442-7. htt://www.sciencemag.org. 2009 – 06 - 18.

Sezer O, Jakob C, Eucker J, Niemoller K, Gatz F, Wernecke K, Possinger K. Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma. J Haematol 2001; 66: 83-88.

Akbulut H, Altuntas F, Akbulut KG, Ozturk G, Cindoruk M, Unal E, Icli F. Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma. 2002 Nov 24; 20(4):184-90.

Broll R, Erdmann H, Duchrow M, Oevermann E, Schwandner O, Markert U, Bruch HP, Windhovel U. Vascular endothelial growth factor (VEGF)—a valuable serum tumors marker in patients with colorectal cancer? Eur J Surg Oncol. 2001 Feb; 27(1):37-42.

Xiong B, Sun TJ, Hu WD, Cheng FL, Mao M, Zhou YF. “Expression of cyclooxygenase-2 in colorectal cancer and its clinical significance”. World J Gastroenterology. 2005 Feb 28; 11(8):1105-8.

Wu AW, Gu J, Li ZF, Ji JF, Xu GW. “COX - 2 expression and tumor angiogenesis in colorectal cancer”. World J Gastroenterology. 2004 Aug 15; 10(16):2323-6.

Peeters CF, de Geus LF, Westphal JR, de Waal RM, Ruiter DJ, Wobbes T, Oyen WJ, Ruers TJ. Decrease in circulating anti-angiogenic factors (angiostatin and endostatin) after surgical removal of primary colorectal carcinoma coincides with increased metabolic activity of liver

metastases. Surgery. 2005 Feb; 137 (2):246-9.

Velde EA, Vogten JM, Gebbink MF, van Gorp JM, Voest EE, Borel Rinkes IH. Enhanced antitumor efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model. Br J Surg. 2002 Oct; 89(10):1302-9.

Zondor SD, Medina PJ. Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacotherapy. 2004 Jul-Aug;38(7-8):1258-64.

Sledge GW Jr, Miller KD. Angiogenesis and antiangiogenic Therapy. Curr Probl Cancer 2002; 26:1-60.

Jain RK. Molecular Regulation of Vessel maturation. Nat Med 2003; 9:685-93

Carmeliet P. VEGF as a key mediator of angiogenesis in Cancer. Oncology 2005: 69 (suppl.3): 4-10

Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9: 669–676. doi: 10.1038/nm0603-669. A concise review of the role of VEGF-A and its receptors in biology and disease.

Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004; 3: 391 – 400. doi: 10.1038/nrd1381. Inhibition of VEGF-A with humanized anti-VEGF-A antibody is effective in treating

human cancer.

Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983; 219: 983 – 985. The initial discovery of a secreted VPF with the characteristics of VEGF-A.

Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 2001;7: 186–191. doi: 10.1038/84635. VEGF-D-stimulated lymphangiogenesis mediates tumor metastasis.

Savory LJ, Stacker SA, Fleming SB, Niven BE, Mercer AA. Viral vascular endothelial growth factor plays a critical role in orf virus infection. J Virol. 2000; 74: 10699–10706. doi: 10.1128/JVI.74.22.10699-10706.2000. Disruption of the VEGF-E gene results in reduced vascularization

of lesions produced by Orf virus infection.

Pinho MSL. Angiogenese: O Gatilho Proliferativo. Ver. Brás. Coloproct. 2005; 25(4): 396-402.

Diaz-Rubio E, Schmoll HJ. The future development of bevacizumab in colorectal cancer. Oncology. 2005; 69 Supply 3:34-45.

Gordon MS, Cunningham D. Managing Patients Treated with bavacizumab in colorectal cancer. Oncology. 2005; 69 Supply 3:25-33.

Downloads

Publicado

25-03-2013

Como Citar

Freitas Almeida MJ. Da angiogénese à terapêutica oncológica antiangiogénica. journal [Internet]. 25 de Março de 2013 [citado 23 de Abril de 2024];(23):9-16. Disponível em: https://onco.news/index.php/journal/article/view/159